Analysis from continued follow-up of Phase 1/2 clinical trial data in Hunter syndrome (MPS II) reinforces potential for tividenofusp alfa (DNL310) to address full disease spectrumLaunch readiness ...

SCOTTSDALE, AZ / ACCESS Newswire / February 5, 2026 / In 2026, many men are facing performance burnout caused by long work hours, high stress, poor sleep, and natural age related hormonal decline.